BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lintuzumab-Ac225 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lintuzumab-Ac225\, from ClinicalTrials.go
 v estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07422363-2929@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Lintuzumab-Ac225: Phase 1 readout est. (NCT07422363)
DESCRIPTION:Lintuzumab-Ac225\, phase 1.\nStudy: Testing the Combination of 
 Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes 
 for Patients With Recurrent Glioblastoma\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lintu
 zumab-ac225#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07422363
URL:https://assetmemo.bio/drug/lintuzumab-ac225#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
